An unexpected drop in September construction spending sent the markets tumbling to a sharply lower close with the Dow plunging 105 points to 18,037. Nasdaq fell 35 points to 5,153.
On the upside
Takeda Pharmaceutical may pay up to $10 billion to acquire Valeant Pharmaceuticals' (NYSE: VRX) Salix business.
Oculus Innovative Science (Nasdaq: OCLS) sold its Latin America assets to Invekra S.A.P.I. de C.V. for approximately $19.5 million in cash.
Organovo Holdings (Nasdaq: ONVO) received strong customer response for its ExVive Human Kidney Tissue.
On the downside
Instructure (NYSE: INST) reported a loss for the third quarter.
Gannett (NYSE: GCI) abandoned its bid to acquire Tronc (Nasdaq: TRNC).
Fourth quarter earnings plunged for Marinemax (NYSE: HZO) to fall short of expectations.
In the broad market, declining issues outpaced advancers by more than 3 to 1 on the NYSE and by nearly 5 to 2 on Nasdaq. The broader S&P 500 dropped 14 points to 2,111. Bitcoin surged $23 to $723.
